Navigation Links
First technology to remove prions that cause vCJD from blood launched

The risk of receiving blood contaminated with variant Creutzfeldt-Jakob (vCJD) prions may no longer be a concern for the thousands of people who require a transfusion. Pall Corporation (NYSE: PLL) announced today the Council of Europe (CE) marking of its Leukotrap® Affinity Prion Reduction Filter System. It is the first and only technology that removes infectious prions that may be the causative agent of vCJD from red cells, the most commonly transfused blood component. Variant CJD, a fatal neurodegenerative disease, is the human form of Bovine Spongiform Encephalopathy (BSE), also known as Mad Cow Disease. The CE mark means the new prion reduction filter meets pan-European essential requirements for safety of medical devices.

"The availability of our prion reduction filter is a seminal event heralding a new era in blood safety," says Eric Krasnoff, Chairman and CEO of Pall Corporation. "We are working very closely with health authorities, starting with the nations hardest hit by vCJD, to help protect the safety of the blood supply and prevent the spread of this insidious disease."

The new prion reduction filter will be evaluated by the United Kingdom (UK) National Blood Service and the Irish Blood Transfusion Service with results expected to be available later this year or in early 2006. Of the 40 million red cell units collected annually across the industrialized world, 2.5 million are collected in the UK and 130,000 in Ireland.

Since the first human case of vCJD was identified in the UK in 1994, there has been a total of 172 cases worldwide in Ireland, France, Italy, the Netherlands, Canada, the United States (US), Japan and Saudi Arabia, with the vast majority (155) in the UK. Since vCJD can be asymptomatic for about 10 to 16 years, there is no accurate way to determine how many people could currently be harboring the disease or the magnitude of future cases. Variant CJD is transmitted by eating contaminated beef and may also be transmitte
'"/>

Source:Pall Corporation


Page: 1 2 3 4

Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes

Post Your Comments:
(Date:11/9/2009)...David Queller and Joan Strassmann argue in a new p...n components, from the genetic level on up, give a...ing is an animal, a plant, a bacteria or a colony...e an organism, such as individuality or even membe... achieve organismality. What is necessary, they ar...
(Date:11/9/2009)... / b3c newswire / - Today, TNO, a Dutch contrac...ican organization for contract research and consul...etter of intent with regard to TNOs dynamic in vi...tent proposes a collaboration in which Seventh Wav...n in North America. The TIM systems will be used t...
(Date:11/8/2009)... a gene through deletion of genetic material on ch...lities in learning and behavior, said a consortium...( www.bcm.edu ) in a report that appears online to...search goes about 95 percent of the way to pinning... to this gene," said Dr. Arthur L. Beaudet ( http:...
Breaking Biology News(10 mins):What is the meaning of 'one'? 2What is the meaning of 'one'? 3TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Developmental delay could stem from nicotinic receptor deletion 2Diagnostic tools and innovative therapies improve patient prognosis 53431 1Diagnostic tools and innovative therapies improve patient prognosis 53431 2Diagnostic tools and innovative therapies improve patient prognosis 53431 3Diagnostic tools and innovative therapies improve patient prognosis 53431 4Diagnostic tools and innovative therapies improve patient prognosis 53431 5Diagnostic tools and innovative therapies improve patient prognosis 53431 6Rock Climbing Injury Rate Soaring 53430 1Rock Climbing Injury Rate Soaring 53430 2Men Around the World Seek Cosmetic Surgery 53428 1Men Around the World Seek Cosmetic Surgery 53428 2
...sor of Clinical Tropical Medicine at the London Sc...d the first Hideyo Noguchi Africa Prize for resear...eir Majesties the Emperor and Empress of Japan at ...ideyo Noguchi Prize aims to award individuals with...research and health services, and seeks to encoura...
... Savage-Rumbaugh, Scientist With Special Standing ...eld of ape language and cognition studies, recentl...egree conferred in the 103-year history of her alm... , Savage-Rumbaugh, an internationally known prim...trated that through early rearing experiences, bon...
...local-source energy. Faster, more reliable technol...anguage. Medical care tailored to your DNA, or neu...ological diseases and injuries. , Five University...tures of energy, health, and technology as part of...they received this year from the National Science ...
Other Biology News:Professor Brian Greenwood awarded first Hideyo Noguchi Africa Award 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 3Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 4Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 5Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4
(Date:11/9/2009)... SAN DIEGO, Nov. 9 NexBio, Inc. an...nnual American College of Allergy, Asthma, and Imm...ntitled "DAS181 (Fludase®), a Sialidase, Decr...matory Effects in Animal Models of Asthma". ,, ...ad spectrum host-targeting drug candidate being st...
(Date:11/8/2009)...ember 6, 2009 As global temperatures and energy c... will be key to a sustainable future. An attract...o studies published online in Genome Research ( ...ome structures of bioethanol-producing microorgani...l in developing new technologies needed to impleme...
(Date:11/6/2009)... AURORA, Ontario, Nov. 6 ...ets: HXBPF) today announced that John Docherty, pr...at Merriman Curhan Ford,s 6th annual Investor Summ...Hotel in New York City. Mr. Docherty will provide...lopment programs L-DOS47 and Topical Interferon Al...
(Date:11/6/2009)... CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolyti...s" or the "Company") today announced updated resul...) in patients with sarcomas metastatic to the lung...ctive Tissue Oncology Society Meeting held in Miam...ster presentation, entitled "A Phase II Study of I...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3
...ence,Corporation (Nasdaq: CSCX ), a global leader...bilitation, and informatics products, announced to...nancial results on Wednesday,April 30, 2008 after ...erence call with analysts and investors for 4:30 p...for the first quarter and current business,develop...
...cancer would find a noninvasive method to determin...ause low levels of oxygen in a tumor have been lin... to image the surrounding organs and tissues at th...umors in mice by Murali Krishna and colleagues, at...importance of this technical advance for furtherin...
...st-selling,biologics developed during the boom yea... hormone (hGH) and insulin, have lost patent,prote...y represent a market,of $40 billion. This opens up...atory hurdles can be overcome, according to a new ...orld Market for Biosimilars., Worldwide interest ...
Other Biology Technology:Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
Luminex 100 IS System from Luminex Corporation
GIBCO Water Distilled Sterile from Invitrogen
GIBCO Water distilled from Invitrogen
Yeast Deletion Parental Strains S. cerevisiae Hansen BY4742 from Invitrogen
Biology Products: